Hims & Hers begins selling branded GLP-1 weight-loss drugs in Australia

Hims & Hers Health said on August 31 that it has begun offering branded GLP-1 weight-loss drugs and men's health treatments in Australia, its first market in the Asia-Pacific region ^[1][2]. The launch follows the company's acquisition of the Australian digital health platform Eucalyptus, which includes the Sydney-based men's telehealth brand Pilot, completed earlier this year ^[1].

Pilot will let Hims offer products ranging from sexual health medications to cholesterol treatments, according to Tim Doyle, a former Eucalyptus chief executive who is now a senior vice president at Hims & Hers ^[1].

"Combining Pilot's deep local knowledge with Hims' global platform gives us a meaningful opportunity to help even more Australians access better, more comprehensive weight-loss care," Doyle said ^[1].

A Hims spokesperson said the company's weight-loss program in Australia may include access to branded GLP-1 medications, but the company did not say which ones ^[1]. In the United States, Hims offers branded weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound ^[1]. Hims will move existing Pilot clinicians onto its own platform and plans to launch its women's health segment in Australia later this year through Juniper, Eucalyptus' women's brand ^[1].

Doyle said the Australian move should give customers easier access to preventive care and cut travel and wait times. "Difficulty of rural access is a big factor in Australia," he said ^[1]. He also said he expects Hims to combine services Australians previously bought separately, along with introducing new treatment options ^[1].

The expansion comes as the company's margins face pressure. Hims said on its second-quarter earnings call that it expects gross margins to remain below historical levels as it accelerates international offerings, even though its international business has helped lift subscriptions and raise monthly revenue per subscriber by 21% from a year earlier ^[1][2]. The company has set a target of $6.5 billion in revenue by 2030 and has been investing in diagnostic testing, manufacturing infrastructure, menopause and hormonal treatments, and international expansion ^[1]. In 2025 it bought Zava, a London-based company that prescribes and delivers weight-loss drugs in the UK, Germany, France and Ireland ^[1].

Doyle said Hims is prioritizing brand visibility and gaining international subscribers, and that the company will improve the efficiency of its international business over the long term ^[1].

An analysis published by Insider Monkey described the same trade-off: Australia adds a sizable market and a ready-made local platform through Eucalyptus, but international expansion is already weighing on gross margins and may keep doing so before the business reaches scale ^[2]. The analysis also said there is no guarantee that Hims' U.S. customer-acquisition model will translate directly to Australia, and that offering branded drugs rather than relying solely on its previous compounded-drug model ties its economics more closely to drug pricing and supply ^[2].

Why it matters for patients

For people in Australia considering GLP-1 treatment, the launch adds a telehealth route to branded medications. Hims' Australian program is built around branded drugs rather than compounded versions, according to the analysis ^[2]. Which specific medicines will be offered through Hims in Australia, at what price, and how prescriptions and shipping will work have not been disclosed ^[1].

Rural access is one stated focus. Doyle said difficulty of rural access is a big factor in Australia and that the service should cut travel and wait times for customers ^[1].

The announcement did not include new clinical data on GLP-1 medications, and no changes to Hims' U.S. offerings were disclosed ^[1]. It also does not change which GLP-1 drugs are approved in the United States, or what they cost there.

What happens next

Hims plans to launch its women's health segment in Australia later this year through Juniper, Eucalyptus' women's brand, and will transition existing Pilot clinicians to its platform ^[1]. The company has not given a date for when its Australian weight-loss program will name the branded GLP-1 medications it offers, and it has not reported subscriber or revenue figures for the Australian business ^[1]. Hims maintains a stated goal of $6.5 billion in revenue by 2030 ^[1][2].